Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy/GSK Partnership Yields First Drug Candidate

This article was originally published in The Pink Sheet Daily

Executive Summary

Ranbaxy will develop a respiratory disease candidate through proof of concept under an expanded discovery agreement inked with GSK in February.

You may also be interested in...



Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year

Indian firm reports 17.95 billion rupees ($460 million) in sales, up from 17.08 billion rupees a year ago, with a 2012 goal of being a top-five generics company.

Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year

Indian firm reports 17.95 billion rupees ($460 million) in sales, up from 17.08 billion rupees a year ago, with a 2012 goal of being a top-five generics company.

Ranbaxy Board Approves Spin-off Of Drug Discovery Company

Ranbaxy Laboratories is moving to "de-merge" its drug discovery activities into a separate company with dedicated resources, the firm announced Oct. 18

Related Content

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel